1. Introduction {#s0005}
===============

Before December 2019, very little was known about the coronaviruses (CoVs) because previously CoVs were not hit the global community so badly even though CoVs have been infected many species including humans and discussed for more than 70 years. [@bb0010] were reported murine virus (JHM) for the first time in 1949. Molecular mechanisms and pathogenesis of different CoVs have been intensely studied in different animal species such as porcine transmissible gastroenteritis virus (TGEV), bovine coronavirus (BCoV), and avian infectious bronchitis viruses (IBV). The CoVs having emergence and re-emergence history causing respiratory and intestinal infections in animals and humans ([@bb0165]). This family of viruses remained unclear because they can only cause common cold symptoms in immune-competent individuals until the outbreak of severe acute respiratory syndrome (SARS) in 2003 ([@bb0265]). Before the SARS epidemic in 2002--03, it was supposed that CoVs are not deadly pathogens to humans. Subsequently, a decade later in 2012, another Zoonotic highly pathogenic coronavirus emerged in Middle Eastern countries caused the Middle East respiratory syndrome (MERS) epidemic ([@bb0290]). The ongoing SARS-CoV-2 pandemic situation got worldwide attention and became the utmost priority of the global health community due to the higher rate of human-human transmission. Previous studies have confirmed that SARS-CoV-2 adopted recombination and mutations strategies that help to adapt rapidly changing host environments through genotype adjustment via reproductive adaptability and ultimately escape from human immune reconnaissance ([@bb0205]).

In a broader perspective, this review will describe the SARS-CoV-2 origins, epidemiology, pathogenesis, clinical manifestations, immune enhancement, genes and their variations, phylogenetic analyses, potential therapeutic strategies and future perspective to summarize approaches for developing broadly effective prevention of Corona Virus Disease-19 (COVID-19).

2. Origin {#s0010}
=========

Coronaviridae family divided into two subfamilies, the coronaviruses, and the toroviruses. All identified CoVs are categorized into four different genera *alpha coronaviruses*, *beta coronaviruses*, *gammacoronaviruses*, and *delta coronaviruses*. The human infecting CoVs belongs to *alpha coronaviruses* and *beta coronaviruses*, whereas *gammacoronaviruses*, and *delta coronaviruses* showed susceptibility for fish and birds as shown in [Fig. 1](#f0005){ref-type="fig"} .Fig. 1Classification of coronaviruses.Fig. 1

All human infecting CoVs can cause mild to severe infection in humans and used spillover intermediate hosts ([Fig. 2](#f0010){ref-type="fig"} ). Earlier to 2019, there were only six CoVs that were known to infect humans and cause respiratory diseases. Four out of six (HCoV-229E, HCoV-OC43, HCoV-NL63, and HKU1) human infecting CoVs can only cause mild upper respiratory disease, and in rare cases, some of them can cause severe infection in infants, young children, and elders ([Fig. 2](#f0010){ref-type="fig"}). Although, SARS-CoV and MERS-CoV which are zoonotic in origin can infect the lower respiratory tract and cause a severe respiratory syndrome in humans ([@bb0050]; [@bb0060]; [@bb0270]). Previously studied known pathogenic coronaviruses are presented in the table ([Table 1](#t0005){ref-type="table"} ).Fig. 2Human infection-causing coronavirus and their origin.Fig. 2Table 1Pathogenic coronaviruses, strain, host, and disease symptoms.Table 1Accession no.VirusStrainHostSymptomsNC_002645.1Human CoV-229EHCoV-229EHumanMild respiratory tract infectionsNC_005831.2Human CoV-NL63HCoV-NL63HumanMild respiratory tract infectionsMH940245.1Human CoV-HKU1HCoV-HKU1HumanPneumoniaKU131570.1Human coronavirus OC43 strainHuman CoV-OC43HumanMild respiratory tract infectionsAY345986Severe acute respiratory syndromeSARS-CoVHumanSevere acute respiratory syndrome,10% mortality rate[NC_045512.2](ncbi-mga:NC_045512.2){#ir0005}Severe acute respiratory syndrome coronavirus 2SARS-CoV-2HumanFever, Cough, Shortness of breath or difficulty breathingMN988668.1Wuhan seafood market pneumonia virus isolate 2019-nCoV WHU012019-nCoV WHU0HumanSevere acute respiratory syndromeMH734115.1Middle East respiratory syndrome coronavirusMERS-CoVHumanSevere acute respiratory syndrome,37% mortality rateDQ811787.1Porcine respiratory coronavirusPRCV/ISU-1PigMild respiratory tract infectionsNC_038861.1Transmissible gastroenteritis virusTGEV/PUR46-MADPigDiarrhea,with100%mortalityinpiglets less than 2-week-oldKU558701Porcine epidemic diarrhea virusPEDV/ZJU-G1-2013PigSevere watery diarrheaKU558701Swine enteric alphacoronavirusSeACoV-CH/GD-01PigSevere and acute diarrhea and acute vomitingNTU336/F/2008Canine CoVCCOVDogMild clinical signs, diarrheaDQ848678.1Feline infectious peritonitis virusFCoV C1JeCatFever, vasculitis, and serositis, with or without effusionsEF424623Bovine CoV/ENTBovine CoV/ENTCowDiarrheaAY394989Equine Severe acute respiratory syndromeEquineCoV/Obihiro12-1HorseFever, anorexia, leucopeniaNC_001846.1Mouse hepatitis virus strain MHV-A59 C12MHV-A59MouseAcute pneumonia and severe lung injuriesNC_010646Beluga whale coronavirus SW1Beluga Whale CoV/SW1WhalePulmonary disease, terminal acute liver failureM21883infectious bronchitis virus strainIBVChickenSevere respiratory diseaseNC_011547.1Bulbul CoV HKU11-934HKU11-934BulbulRespiratory disease (collected from the respiratory tract of dead wild birds)NC_009657Sparrow coronavirus HKU17HKU17SparrowRespiratory disease (collected from the respiratory tract of dead wild birds)MG772934.1Bat SARS-like coronavirusBat-SL-CoVZXC21BatFever, Cough, Shortness of breath or difficulty breathingMG772933.1Bat SARS-like coronavirusBat-SL-CoVZC45BatFever, Cough, Shortness of breath or difficulty breathing

SARS and the MERSCoVs belong to *beta coronaviruses* have been characterized as they were transmitted from animals to humans and caused severe disease outbreaks in the past. SARS-CoV was transmitted in humans from bats via the intermediary host of palm civet cats ([Fig. 2](#f0010){ref-type="fig"}) in the Guangdong province of China and about 8422 infected cases with 916 deaths were recorded and the mortality rate was 11%. Furthermore, a decade later in 2012, a bat origin virus MERS-CoV epidemic was emerged in Saudi Arabia through the dromedary camels ([Fig. 2](#f0010){ref-type="fig"}) and caused 858 deaths out of 2494 infected people with a 34% fatality rate ([@bb0225]).

Now, in late December 2019, a couple of patients were diagnosed with concentrated pneumonia with an unknown etiology in Wuhan, China ([@bb0015]; [@bb0125]; [@bb0160]). The newly emerged novel CoV retained 99.8--99.9% nucleotide sequence homology with *beta* bat CoVs that directed the reemergence of another viral strain, later entitled as SARS-CoV-2 ([@bb0210]) and genetic analysis of the SARS-CoV-2 represented genetic similarity 50% with MERS-CoV and 80% with SARS-CoV ([@bb0160]; [@bb0210]; [@bb0205]).

3. Epidemiology {#s0015}
===============

As of 03 June 2020, a total of 6,467,229 cases of COVID-19 have been confirmed worldwide including 382,766 deaths ([@bb2005]). COVID-19 as an acute respiratory infectious disease, primarily spreads by the mean of the respiratory tract, via droplets, respiratory secretions emitted from an infected person or direct contact for a low infective dose ([@bb0155]; [@bb0145]). Significantly high level of viral loads was also observed in the nasal cavity as compared to the throat where the viral load was the same between symptomatic and asymptomatic people ([@bb0300]). Patients can be a career of infection even on clinical recovery and few people may act as a strong candidate to spread the infection, for example, an infected UK resident caused 11 people to infect by COVID-19. The incubation period of this disease ranges from 2 to 14 days (median 5 days) ([@bb0225]). SARS-CoV-2 virus responds to the same receptor, angiotensin receptor 2 (ACE2), to enter the respiratory mucosa as the SARS-CoV entry receptor ([@bb0070]).

4. Pathogenesis {#s0020}
===============

The SARS-CoV-2 is a respiratory system targeting virus therefore the prime pathogenesis of the COVID-19 severe pneumonia, RNAaemia, combined with the incidence of ground-glass opacities, and acute cardiac injury. Also, some patients were exhibited non-respiratory symptoms such as the acute liver and heart injury, kidney failure, diarrhea, implying multiple organ involvement ([@bb0065]; [@bb0105]; [@bb0115]; [@bb0120]; [@bb0235]; [@bb0260]). Crucially, viral replication is supposed to occur in the mucosal epithelium of the upper respiratory tract (nasal cavity and pharynx), in addition, proliferation is in the lower respiratory tract and gastrointestinal mucosa that results in the mild viremia ([@bb0275]; [@bb0285]). [Fig. 3](#f0015){ref-type="fig"} is a hypothetical explanation of the pathogenesis of SARS-CoV-2 infection.Fig. 3Pathogenesis of SARS-CoV-2 infection.Fig. 3

5. Clinical manifestations {#s0025}
==========================

The clinical features of COVID-19 range from an asymptomatic condition to acute respiratory distress syndrome and multiple organ dysfunction, so it is difficult to distinguish it from other respiratory infections. Almost 5.2 days\' time period of incubation is required for the appearance of COVID-19 symptoms ([@bb0155]), and after one week of the onset of disease patients experience pneumonia, the respiratory failure that leads to death ([@bb0060]). The primary and common symptoms at the early stage of COVID-19 infection are fever, cough, and fatigue, whereas other symptoms such as sputum, headache, hemoptysis, diarrhea, dyspnoea, and lymphopenia have also been observed ([@bb0040]; [@bb0110]; [@bb0120]; [@bb0180]; [@bb0100]; [@bb0255]). Clinical findings related to acute lung injury, ARDS, shock, kidney injury can cause death ([@bb0040]; [@bb0180]; [@bb0200]). The shorter period was witnessed in patients with the age of more than 70-years old ([@bb0040]). Incompatible death results are more common in the elderly and those with underlying co-morbidities (50--75% of fatal cases). In the adult, aged patient\'s fatality rate ranges between 4 and 11% while the overall fatality rate varies between 2 and 3% ([@bb0180]; [@bb0215]).

In another study, similar symptoms for COVID-19 and earlier *betacoronavirus* have been observed in chest CT scans ([@bb0120]). Although, some distinctive clinical features in COVID-19 exist including lower airway and upper respiratory tract symptoms like rhinorrhea, sneezing, and throat soring ([@bb0005]; [@bb0150]). Similarly, chest radiography of some patients showed an infiltrate in the upper lobe of the patients ([@bb0200]). Whereas, gastrointestinal symptoms like diarrhea were also diagnosed in some COVID-19 patients ([@bb0095]), which were also found in MERS-CoV or SARS-CoV patients ([@bb0005]; [@bb0150]).

6. Immune enhancement against COVID-19 {#s0030}
======================================

Antibody-dependent enhancement (ADE) occurs when non-neutralizing antiviral proteins facilitate virus entry into host cells, leading to increased infectivity in the cells. Recently, ADE is proposed as a responsible for the inflammation because of SARS-CoV-2 infection ([@bb0090]). ADE can interact with virus--antibody complexes their receptors, and increasing the target cell infection ([@bb0240]). The interaction between specific receptor and virus complex can activate both pathways such as inflammatory responses and viral replication in the patients ([@bb0095]). In another study, loss of ACE2 function is related to acute lung injury because the ACE2downregulation can result in RAS dysfunction, and endorse the inflammation that causes vascular permeability ([@bb0135]). These biomarkers propose both a molecular description and a feasible treatment for acute respiratory distress syndrome (ARDS) following SAS-CoV-2 infection. Moreover, in severe cases, CD4 and CD8 T cells exhibited hyper-activation and high level of expression of cytotoxic granules CD8 T cells and pro-inflammatory CD4 T cells suggested immune responses against viral attack ([@bb0280]). Additionally, lymphopenia is also reported as a common characteristic of COVID-19 which is a serious reason account for severe infection and a higher rate of mortality ([@bb0120]; [@bb0295]). The virus can remain viable on surfaces in suitable conditions and can be smashed within 60 s by common disinfectants like sodium hypochlorite and hydrogen peroxide ([@bb0140]).

7. Genes involved {#s0035}
=================

Interestingly, the histopathologically ARDS has been identified in the patients of all type of cases such as SARS-CoV, MERS-CoV, and SARS-CoV-2 ([@bb0080]; [@bb0175]; [@bb0280]). Elevated levels of cytokines and chemokines in COVID-19 patients including IL1β, IL1RA, IL7, IL8, IL9, IL10, basic FGF2, GCSF, GMCSF, IFN γ, IP10, MCP1, MIP1 α, MIP1 β, PDGFB, TNF α, and VEGFA were also observed. Additionally, a few patients with a severe infection in the intensive care unit also showed increased levels of pro-inflammatory cytokines including IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1 α, and TNF α that were responsible for disease severity ([@bb0120]). After genetic variability, the cytokines were studied and the incidence of ARDS was evidenced. Many candidate genes, i.e. ACE2, IL-10, TNF, VEGF are believed to be associated with ARDS development or outcome ([@bb0170]). In addition, the increased levels of IL-6 and IL-8 were confirmed to be associated with ARDS ([@bb0250]).

8. Genomic variations in SARS-CoV-2 {#s0040}
===================================

The genetic information of any life is preserved in its genome, and the annotation is the first step to explain the sequence. While the length of the SARS-CoV genome is above \~29 kb, it appears that only a few coding genes do not match the general characteristics of the viral genome and the group of minimal hereditary data. In previous studies, 156 variants were found in 95 samples available on NCBI databases and 116 variants were identified uniquely. In addition, these variants have 46 missense, 52 synonymous, 2 insertions, 1 deletion, and 14 non-coding alleles. The most common variant were found 8782C\>T (ORF1ab) in 13 samples, 28144T\>C (ORF8) in 14 samples and 29095C\>T (N) in 8 samples. The 8782C\>T and 28144T\>C coincided. Also, 29095C\>T was located in one of these subsets. Both 8782C\>T and 29095C\>T were synonymous; However, 28144T\>C causes amino acids to replace L84S in ORF8. For 46 missense variants, ORF1ab has 24 variants, that occupies 2/3 of the entire genome. All non-coding mutations are within 3′UTR or 5′UTR regions that have C\>T changes ([@bb0220]).

In another study, [@bb0205] were compared the Envelop (E), Nucleocapsid, Membrane (M), and Spike protein of SARS-CoV-2 with SARS-CoV. It represented 7%, 8%, 7% and 19% amino acid sequence variations in E, M, N and S regions respectively ([Table 2](#t0010){ref-type="table"} ). Moreover, they also presented nine putative recombinants in SARS-CoV-2 and hypothesized that SARS-CoV-2 is the recombinant of SARS and SARS-like CoVs. Six out of nine recombinants are in S motif which is important for viral pathogenicity. Furthermore, SARS-CoV-2 receptor-binding domain (RBD) was analyzed and showed 73% sequence similarity with the pandemic RBD ([@bb0205]). While the binding free energies that were calculated for human ACE2 and S protein binding complexes and SARS-CoV-2 free binding energy increased up to 28 kcal mol^−1^, representing higher binding affinity to the human ACE2 receptor ([@bb0205]).Table 2SARS-CoV-2 homology and genetic variations in different genomic regions with respect to SARS-CoV.Table 2Envelop proteinMembrane proteinNucleocapsid proteinSpike proteinHomologyGenetic variationsHomologyGenetic variationsHomologyGenetic variationsHomologyGenetic variations93%07%92%08%93%07%81%19%[^1]

9. Evolution of SARS-CoV-2 {#s0045}
==========================

Distinguishing the origins of an emerging pathogen can be critical during the beginning periods of an outbreak as it may allow for containment measures to be precisely targeted. Before December 2019, four strains of Betacoronavirus, HKU1, MERS-CoV, OC43, and SARS-CoV, had been accounted to cause severe human infections ([@bb0185]). The fifth strain, a novel beta coronavirus SARS-CoV-2 causing human pneumonia, was first detailed in Wuhan, Central China ([@bb0185]). Coronaviruses are naturally hosted and developmentally formed by bats. To do this, it has been proposed that the majority of human coronaviruses are derived from the bat reservoir ([@bb0245]). Several teams have recently confirmed the genetic similarity between SARS-CoV-2 and the beta betacoronavirus of the subgenus Sarbecovirus ([@bb0245]). The genome sequence of the new virus is 96.2% identical to that of the bat. SARS-related coronavirus (SARSr-CoV; RaTG13) has been collected in Wuhan, China, but is not identical to the genome of SARS-CoV (about 79%) or MERS-CoV (approximately 50%) as shown in [Fig. 4](#f0020){ref-type="fig"} . Replacement and recombination of nucleotides has been proposed a mechanism of viral development in nature ([@bb0205]; [@bb0195]).Fig. 4Whole genome-based phylogenetic tree of CoVs constructed with the maximum-likelihood method using BEAST with GTR + I + G as the nucleotide model of substitution.Fig. 4

In addition, SARS-CoV-2 uses the same receptor, angiotensin II converting enzyme (ACE2) as SARS-CoV. Although the specific pathway of transmission from natural reservoirs to humans is unclear ([@bb0190]; [@bb0245]), several studies have shown that pangolin may confer partial *spike* genes to SARS-CoV-2; The critical functional regions of the spike protein SAR-CoV-2 are nearly the same as those defined in viruses isolated from a pangolin ([@bb0245]).

10. Potential therapeutic strategies {#s0050}
====================================

In the early era until 1960 CoVs were thought to be simple viruses causing flu-like symptoms. In later studies, it was proved that CoV is a more serious and dangerous virus and it causes SARS epidemics (2002 to 2003) ([@bb0045]; [@bb0155]; [@bb0260]). The outbreak of MERS in Middle Eastern Countries in 2012 posed a very serious condition that proved it more dangerous ([@bb0030]; [@bb0045]; [@bb0155]; [@bb0260]).

To manage the COVID-19 antipyretics and analgesics are directed. Moreover, hydration is maintained and also the respiratory system is supported by mechanical ventilation or extracorporeal membrane oxygenation. In case of bacterial infection along with COVID-19 antibiotics are found beneficial. We may use chloroquine and hydroxychloroquine having synergistic effects, but further studies needed ([@bb0075]; [@bb0180]). Also, we have the option of Favipiravir and Remdesivir which were trialed by China and Japan but further studies are required ([@bb0090]; [@bb0130]).

Also, many evidences showed that convalescent plasma from patients recovering from viral infections can be used as a treatment in patients infected with SARS-CoV-2 ([@bb0055]). In addition, by influencing ACE2 levels, cardiovascular diseases and/or their treatment can play an important role in the infectivity and consequences of COVID - 19. Whether ACE2 treatment or upregulation caused by the disease immediately affects the COVID - 19 course ([@bb0230]). During this global emergency of the COVID-19 pandemic, strategies are taken into account to quickly monitor the timeline for licensing a vaccine against COVID-19, especially by compressing the generally long duration of phase II--III study ([@bb0035]; [@bb0075]; [@bb0025]; [@bb0085]).

11. Conclusion {#s0055}
==============

It is widely accepted that there are many viruses in their natural reservoirs for a very long time. The constant spread of viruses from natural hosts to humans and other animals is largely due to human activities. Data collected on genetic evolution, receptor binding and pathogenesis have shown that SARS-CoV is most likely caused by bats by sequential recombination of bat SARS-CoVs. The rapid proliferation of SARS-CoV-2 raises many questions, whether its development is driven by the mutation or any other mechanisms. So the Government and health authorities must develop and implement the guidelines for researchers and the public for the development of drugs and vaccines to reduce the spread rate of COVID-19.
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[^1]: SARS-CoV-2 (Wuhan-Hu-1-CoV) and SARS-CoV (GZ02).
